|
HSP90AA1
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
This review summarizes current knowledge on the role of HSP90 protein in cancer with focus on melanoma, and provides an overview of structurally different HSP90 inhibitors that are considered as potential therapeutics for melanoma treatment.
|
31659567 |
2020 |
|
HSP90AA1
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.
|
29507054 |
2018 |
|
HSP90AA1
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Our studies support a role for 17-AAG and HSP90 inhibition in enhancing cellular immunotherapy for melanoma.
|
29481571 |
2018 |
|
HSP90AA1
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
We evaluated apoptosis in a melanoma cell line treated with the Hsp90 inhibitor 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), in hyperthermic conditions.
|
29433909 |
2018 |
|
HSP90AA1
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
HSP90 inhibitors warrant further evaluation in combination with current standard-of-care BRAF plus MEK inhibitors in BRAF<sup>V600</sup>-mutant melanoma.<i>Clin Cancer Res; 24(22); 5516-24.
|
29674508 |
2018 |
|
HSP90AA1
|
melanoma
|
0.100 |
AlteredExpression |
BEFREE |
The baseline serum HSP90 levels of melanoma patients
|
28440609 |
2017 |
|
HSP90AA1
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
These results demonstrate that the combination of HSP90 and PI3K/mTOR inhibitors could be an effective therapeutic strategy that target the main survival pathways in melanoma and must be considered to overcome resistance to BRAF inhibitors in melanoma patients.
|
28774796 |
2017 |
|
HSP90AA1
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Efforts have been taken to develop monoclonal antibodies (mAbs) and antibody fragments targeting extracellular Hsp90 and Hsp70, alone or conjugated with standard anticancer agents, to control several types of cancer, such as breast, colon, prostate or melanoma.
|
27881057 |
2017 |
|
HSP90AA1
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG.
|
27045471 |
2016 |
|
HSP90AA1
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
Here, we examined the activity of ganetespib, a small-molecule inhibitor of Hsp90, in melanoma lines harboring the BRAF(V600E) mutation.
|
24398428 |
2014 |
|
HSP90AA1
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
HSP90 is functionally important for melanoma cells and HSP90 inhibitors such as ganetespib could potentially be effective therapeutics for melanoma with various genetic mutations and acquired resistance to B-RAF inhibition.
|
23418523 |
2013 |
|
HSP90AA1
|
melanoma
|
0.100 |
GeneticVariation |
BEFREE |
Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.
|
23538902 |
2013 |
|
HSP90AA1
|
melanoma
|
0.100 |
AlteredExpression |
BEFREE |
A novel mass spectrometry-based pharmacodynamic assay was developed to measure intratumoral HSP70 levels following HSP90 inhibition in melanoma cell lines, xenografts, and melanoma biopsies.
|
22351686 |
2012 |
|
HSP90AA1
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Functional analysis demonstrated that HSP90 small-interfering RNA transfection reduced the migration ability and metastasis of melanoma.
|
21697887 |
2011 |
|
HSP90AA1
|
melanoma
|
0.100 |
AlteredExpression |
BEFREE |
In mesenchymal tumours, HSP90 overexpression was found in 66.7% of malignant peripheral nerve sheath tumours, 83.3% of leiomyosarcomas, and 100% of melanomas.
|
20546334 |
2010 |
|
HSP90AA1
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Our findings provide a basis for using metabolic changes as non-invasive indicators of Hsp90 inhibition and potentially as biomarkers of anticancer activity with Hsp90 drugs in malignant melanoma and possibly in other cancers.
|
21037799 |
2010 |
|
HSP90AA1
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
These preliminary results suggest that BRAF and NRAS mutation status should be determined in prospective phase II studies of HSP90 inhibitors in melanoma.
|
18375819 |
2008 |
|
HSP90AA1
|
melanoma
|
0.100 |
AlteredExpression |
LHGDN |
Immune expression and inhibition of heat shock protein 90 in uveal melanoma.
|
18245548 |
2008 |
|
HSP90AA1
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Future trials in melanoma should focus on a more potent hsp90 inhibitor or a formulation that can be administered chronically for a more prolonged suppression of the MAPK pathway.
|
19088048 |
2008 |
|
HSP90AA1
|
melanoma
|
0.100 |
Biomarker |
BEFREE |
Hsp90 inhibition represents a therapeutic strategy for the treatment of melanoma.
|
16371460 |
2006 |
|
HSP90AA1
|
melanoma
|
0.100 |
AlteredExpression |
BEFREE |
While melanocytic nevi show discrete Hsp90 expression only in a minor fraction (2/9), malignant melanomas and metastases show a positive Hsp90 immunohistochemistry in the majority of cases; (7/9) and (13/14), respectively.
|
15009113 |
2004 |
|
HSP90AA1
|
melanoma
|
0.100 |
AlteredExpression |
LHGDN |
From these data we conclude that Hsp90 is present in advanced malignant melanomas and may have a stabilizing effect on the cellular functions in proliferating cells of melanocytic lesions and could thereby be a prerequisite for the tumor progression.
|
15009113 |
2004 |